Condition
EBV-Related Lymphoproliferative Disorder
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Suspended1
Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06741072Phase 1Suspended
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
NCT04664179Phase 1Recruiting
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
NCT05011058Phase 2Terminated
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
Showing all 3 trials